Background: Universal access to drug susceptibility testing is key to ending TB.
INTRODUCTION
The proportion of tuberculosis (TB) cases that are multi-drug resistant (MDR) is increasing worldwide. Although set against a background of a falling global incidence of TB, the net effect is that the number of MDR-TB cases continues to grow. 1 Improving the treatment success rate for MDR-TB requires each patient to receive an individual antimicrobial regimen tailored to maximize efficacy whilst minimizing toxicity; this necessitates being able to measure minimum inhibitory concentrations (MIC), to direct both the choice of drug and dose. Universal access to prompt and comprehensive drug susceptibility testing (DST) is therefore a key component of the WHO's End TB Strategy. 2, 3 Although molecular approaches have the potential to deliver universal DST methods, they require further development work and any resulting solutions are likely to be expensive.
Liquid and solid media assays that measure MICs for TB exist, [4] [5] [6] [7] [8] [9] but are time consuming and, often, expensive. Microtitre plates offer a way of testing in parallel the effectiveness of a large number of drugs at a range of concentrations on small aliquots from a single clinical isolate. Broth microdilution methods, including several using colorimetric indicators, have previously been developed that assess the MICs for a panel of compounds using a single microtitre plate. 5, 10, 11 A dry-format, 96-well microtitre plate assay (the Sensititre™ MYCOTBI plate; Thermo Fisher Scientific Inc., USA) containing 12 drugs has been commercially available since 2010 and early validation studies have returned promising results. [12] [13] [14] [15] [16] No plate-based assays, however, have so far included both new and re-purposed drugs that will be key to the successful treatment of individual MDR-TB cases in the future.
In this paper, we validate a bespoke, dry-form 96-well microtitre plate (UKMYC5) that has been designed by the global CRyPTIC (Comprehensive Resistance Prediction MATERIALS AND METHODS Participating laboratories. Vials containing twenty external quality assessment (EQA) TB strains were distributed by the WHO Supranational Reference Laboratory at San Raffaele Scientific Institute (SRL), in Milan, Italy, to six other participating laboratories ( Figure 1A ). These were located in Germany (Institute of Microbiology and Laboratory Medicine, IML red GmbH, Gauting), UK (Public Health England Figure 1B & S1, available as Supplementary data at JAC Online). One contained the H37Rv Mycobacterium tuberculosis reference strain ATCC 27294 (GenBank AL123456) 17 and was labelled as such. Eleven EQA strains were duplicated (one of which was also H37Rv) by the SRL prior to sending, along with one representative of eight additional EQA strains, bringing the total to 31 culture vials containing nineteen distinct strains. All vials, except the labelled H37Rv vial, were labelled CRY-1 to CRY-30, and therefore were blinded.
Preparation of replicates.
Ten replicates were derived from the unblinded H37Rv ATCC27294 vial ( Figure 1B) , each being sub-cultured on solid media as described below before being subbed onto a UKMYC5 plate. Two replicates were created from each of the remaining thirty vials and, again following sub-culture, were inoculated onto a UKMYC5 plate. Each participating centre therefore tested up to 70 UKMYC5 plates ( Figure 1C ). The UKMYC5 plate was designed by the CRyPTIC consortium   and manufactured by Thermo Fisher Scientific Inc., UK. Fourteen anti-TB drugs   (rifampicin, rifabutin, isoniazid, ethambutol, levofloxacin, moxifloxacin, amikacin, kanamycin, ethionamide, clofazimine, para-aminosalicylic acid, linezolid, delamanid and bedaquiline) were included, at 5 to 8 doubling dilutions ( Figure S1 , Table S1 ). Janssen Pharmaceutica and Otsuka Pharmaceutical Co., Ltd provided, respectively, bedaquiline and delamanid pure substances. Although pyrazinamide-only plates containing lyophilised substance in different stocks were tested, poor performance due to suboptimal broth pH conditions resulted in pyrazinamide being excluded from UKMYC5.
UKMYC5 design.

Inoculation protocol. Laboratory scientists from all centres received training in plate
inoculation and reading at the SRL. The standard operating procedure involved preparing a 0.5 McFarland suspension in saline tween with glass beads (Thermo Fisher, Scientific Inc., USA) from 20-25 day-old colonies (or no later than 14 days after visible growth) grown on Löwenstein-Jensen or 7H11 agar media after initial MGIT culture. Suspensions were diluted 100-fold with the addition of 100 µL of the suspension to 10 mL of enriched 7H9 broth. Aliquots of 100 µL of standard 1.5x10 5 CFU/mL inoculum (approximate range 5x10 4 -5x10 5 ) were dispensed into wells by the semi-automated Sensititre™ Autoinoculator (Thermo Fisher, Scientific Inc., USA). Figure S3 ).
Measurement of MICs.
In each centre, two laboratory scientists independently read each microtitre plate using three different methods (Thermo Fisher Sensititre™ Vizion™ Digital MIC viewing system, a mirrored box and an inverted-light microscope) at 7, 10, 14 and 21 days post-inoculation ( Figure 1D ). MIC results and additional data were recorded locally onto paper and into a shared web-enabled database (Table S2 ). An image of each plate was captured using the Vizion™ and was stored and subsequently analysed by software, the Automated Mycobacterial Growth Detection Algorithm (AMyGDA). 18 AMyGDA analysis was performed at the University of Oxford ( Figure S3 ). Figure   1B ) were phenotypically characterised by BACTEC™ MGIT960 (BD Lifesciences, New Jersey, USA), Middlebrook 7H10/7H11 agar dilution method (Table S3 ) and
+
(with the exception of ethionamide and para-aminosalycilic acid) resazurin microtitre assay (REMA , Table S4 ) for drugs for which the WHO has endorsed critical concentrations (CCs). 19 All strains were also whole genome sequenced; genomic DNA was extracted from Löwenstein-Jensen cultures using either FastPrep24 for cell lysis and ethanol precipitation or the cetyl-trimethylammonium bromide method as described elsewhere. 20 According to the International Organization for Standardization (ISO-20776-2), a clinical antimicrobial susceptibility test is required to have a reproducibility of ≥ 95 %. 22 To assess the reproducibility within a site, the mode MIC for each drug was computed for that site, pooling the results across reading methods, days, replicates and readers. To test the reproducibility between sites, the mode was calculated only for each drug, pooling the results also across sites (besides reading methods, days, replicates and readers). We next compared UKMYC5 MICs to MICs obtained by other DST methods -this is required to be ≥ 90% according to ISO-20776-2. 22 Results were assessed in three ways: (i) the OEA between the UKMYC5 and a reference method was calculated, (ii) the categorical agreement was defined as concordant reporting of either sensitivity or resistance as defined by the critical concentration (CC) of the comparator phenotypic test (if the MIC was lower or equal to the CC the strain was defined as susceptible, otherwise it was defined as resistant). Finally, (iii) the conditional agreement was defined as resistance by the comparator method and a MIC equal to or higher than the CC on the UKMYC5, or susceptibility by the comparator method and a MIC equal to or lower than the CC plus one doubling dilution on the UKMYC5. 11
RESULTS
The proportion of plates that can be read
The proportion of readable results (defined in the Materials and Methods) increased with elapsed time since inoculation, from 66.5% at day 7, to over 90% at day 14, to 96.8% at day 21 (Figure 2A ).
For Site F the proportion of readable results was anomalously high (> 94%), regardless of reading day ( Figure S4A ), yet the reproducibility within the site was anomalously low, varying between 77.3%-80.2% depending on the reading day ( Figure S4C ). Site F also had an anomalously low between site reproducibility of only 72.2%-75.3% ( Figure S4D ). Logistic mixed-effect models confirmed that for Site F between reader OEA and within and between laboratory reproducibilities were all significantly lower than the other laboratories (p<0.001 for all comparisons; Table   S7 ). Data from Site F was consequently excluded from subsequent analyses.
Overall within and between laboratory reproducibility.
At least 92% of all MICs read by two scientists from the same laboratory were in overall essential agreement (OEA, within a doubling dilution), regardless of reading day or method ( Figure 2B 
Selection of reading day and method.
After 7 days, only between 57.8%-66.1% of results were readable, depending on the method used, compared to over 88% at day 14, and between 95.9%-97.6% at day 21
( Figure 2A) . The corresponding logistic mixed-effects model demonstrated that significantly fewer results were readable at day 7 and 10 than at day 14, and that significantly more were readable at day 21 compared with day 14 (p<0.001 for all comparisons, Table S8 ). The proportion of results readable by inverted-light microscope or mirrored box was significantly lower than for Vizion™ (p<0.001 in both instances, Figure 2A , Table S8 ).
The OEA between two scientists examining the same plate within a laboratory increased with time ( Figure 2B ). For Vizion™ and mirrored box, the OEA was >95% for all reading-days, while for the inverted-light microscope it increased from 92.7% at day 7 to 96.8% at day 21 ( Figure 2B ). The corresponding model showed there was significantly lower OEA between readers when they used the inverted-light microscope compared to the Vizion™, or when they read the plates at day 7 compared to day 14 (p<0.001 for both comparisons, Table S8 ).
Overall, the greatest reproducibility (both within and between laboratories) was observed at day 14 ( Figure 2C & 2D) , with both Vizion™ and mirrored box being 95% and 92% reproducible within and between sites, respectively. For the inverted-light microscope, the corresponding reproducibilities were 92.9% and 89.9%, respectively.
The logistic mixed-effects models confirmed that within and between site reproducibility for the inverted-light microscope was overall significantly lower with respect to Vizion™ (p<0.001 for all, Table S9 ). The Sensititre™ Vizion™ Digital MIC Viewing System was therefore selected for all subsequent analyses, although we note that the mirrored box also performed well. The individual MICs measured using Vizion™ were then analyzed to establish the optimal reading-day for each drug ( Figure S5 ). Para-aminosalicylic acid showed the lowest OEA between readers at each reading day and the lowest reproducibility both within and between sites at days 10, 14 and 21. The results of the corresponding logistic mixed-effects models (Table S10) showed that, overall, readings had a significantly lower probability of being reproducible within and between sites at days 7 and 21, than at day 14 (p=0.001 and p=0.004, respectively for day 7, and p=0.001 and p<0.001 respectively for day 21). Reproducibility was similar at days 10 and 14
(p=0.465 and p=0.784, respectively). Because fewer results were readable after 10 days, reading day 14 was preferred and was used in subsequent analyses. MICs read using the combination of Vizion™ and UKMYC5 plate at day 14 are ≥ 95% reproducible for the same plate read by different readers or different plates, both at the same laboratory, but the reproducibility between sites (i.e. same strain, but different plate, reader and laboratory) is 92%, which is below the required threshold of 95%, although this is a very stringent test. 22 Reproducibility was assessed also on an individual drug basis by using rifampicin as a reference standard ( Figure S5 & Table S10 ). Although there was a statistically significant difference between many drugs, the greatest difference was seen for paraaminosalicylic acid where the reproducibilities within and between sites were significantly lower than rifampicin (p<0.001).
Results with AMyDGA software
MICs measured from photographs of the UKMYC5 plates using the AMyGDA software 18 were compared with those based on the Vizion™ reading method. The OEA between the two methods was above 87% for all days and increases with time since inoculation (from 87.9% at day 7, up to 93.8% at day 21, Figure 3 ). At day 14, the OEA between readings by AMyGDA and Vizion™ is above 90% for all drugs, except for moxifloxacin (89.3%) and para-aminosalicylic acid (73.8%), and therefore satisfies ISO-20776-2. 22 Using a logistic mixed-effect model, we found that the overall OEA at days 7, 10 and 21 is not significantly different from the overall OEA at day 14 (p=0.143, p=0.479 and p=0.525, respectively, Table S11 ). The OEA between Vizion and AMyGDA was not significantly different for all drugs at day 14 (Table   S11 ). For all strains, the mode of UKMYC5 MICs was calculated by drug and it was compared with the categorical results (susceptible or resistant) obtained from MGIT and APM, for drugs with established breakpoints ( Figure 5) 13, 19, 24 . Categorical and conditional agreement between UKMYC5 MICs and those obtained from MGIT and the APM were also computed (Table S12 ). To infer 'sensitivity' or 'resistance' using the UKMYC5 plate, we assumed shared breakpoints with each comparator method (APM or MGIT). Discrepancies are shown in Table S13 . 
Comparison between genotype and UKMYC5 results
For all drugs, the presence of mutations in genes in which there is a high confidence that they confer resistance was associated with MICs greater than observed in wild type strains ( Figure 6 ). 25 Mutations whose role in the drug resistance was not well established in the literature were included in the analysis. Only bedaquiline, ethambutol, linezolid and the fluoroquinolones showed some overlap in MICs between wildtype strains and strains containing mutations in genes associated with resistance. For linezolid, no difference of MICs was observed between wild type and mutant strains, but this was expected since these mutations were shown to be susceptible by MGIT and APM (Table S6) , although mutations in the rrL gene have been reported to shift MICs. 26 As expected, mutations associated with low-level resistance, such as inhA_C-15T, were associated with smaller MIC increases than mutations in katG that is associated with high-level resistance ( Figure S7 ). 27 Interestingly, the EQA panel included two isolates that were resistant to delamanid according to the APM. One of these had a mutation in the ddn gene, and the other, in Rv1173. The ddn mutation was associated with higher MICs than the Rv1173 mutation ( Figure S7) . 
DISCUSSION
Broth-based microdilution methods for TB DST have been proposed in the past that either directly 8 or indirectly 5,10,11 measure mycobacterial growth at a range of drug concentrations, potentially enabling the determination of MIC values. In 2011, the WHO examined whether non-commercial microdilution assays would be suitable to screen patients at risk of MDR-TB and conditionally recommended their use 28 .
Subsequent studies assessed their performance [12] [13] [14] and established MIC distributions for the H37Rv reference strain, 15, 16 demonstrating a good correlation with reference methods.
This validation study moves the field forward: UKMYC5 is the first microtitre plate assay to incorporate both new (delamanid, bedaquiline) and repurposed drugs (linezolid and clofazimine) in a dry-well format that is convenient to transport and store. In this paper, we have demonstrated that the measurement of MICS within and between participating laboratories is reproducible for 13 of the 14 drugs on the plate.
Fourteen days after inoculation was shown to be the optimal time to read a plate and the Thermo Fisher Sensititre™ Vizion™ Digital MIC viewing system was selected as the optimal reading method. We note, however, that the mirrored box performed equally well and, since it is cheaper, is likely to be a better solution in low-income countries. The Vizion™, however, also allowed us to photograph each plate, thereby not only providing an audit trail but also enabling the use of the AMyGDA software.
By using a well characterised set of nineteen EQA strains we have been able to determine the conditional agreement with results from alternative MIC-determining DST assays. Assuming that the critical concentrations (CC) for the UKMYC5 was identical to each comparator method allowed the categorical agreement with these assays to also be assessed. In all cases, cross-comparisons demonstrated encouraging consistency. Furthermore, mutations in genes that are known to confer resistance had a clear impact on MIC values. Taking these results together, we conclude that that the UKMYC5 plate has the potential not only to be used as a research tool but also as a clinical diagnostic assay. images of all the plates as part of an audit trail. As these images can be read automatically by the AMyGDA software, we are evaluating whether incorporating the AMyGDA software within our standard operating procedure will allow us to detect significant differences in plate interpretation much earlier.
The UKMYC5 plate does have several limitations; these include the need for a preculture step, entailing a delay of up to six weeks before the plate is inoculated. This currently prevents the rapid turn-around of results, however, we expect this time could be reduced significantly by further development to define the optimal inoculum from MGIT culture. Given the notable advantages inherent in this microtitre plate, such further development work should clearly be pursued. The UKMYC5 plate would also benefit from a minor re-design; PAS, which performed poorly, should be excluded and the vacated wells used to expand the range of concentrations for drugs where measurements were most frequently reported at the extremes of the dilution range.
How the UKMYC5 microtitre plate could be optimally incorporated in a clinical laboratory's workflow remains to be determined, but the numerous advantages it offers suggests its adoption should be pursued with vigour. The Foundation for Innovative and New Diagnostics (FIND) have already expressed interest in pursuing endorsement by the WHO (personal communication, Claudia Denkinger). In parallel, its impact on our understanding of the effect of genomic mutations on the MICs of various drugs is likely to inform the WHO's planned assessment of WGS-based DST in 2018. 1 Whether it be through direct measurement of MICs, or predictions of MIC from genomic data, a new era of quantitative TB DST may be with us. 
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